The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
- Trial number:
- NCT04664829
- Trial phase:
- 1
- Study type:
- Chemotherapy
- Overall status:
- Recruiting
Study start date
October, 2020
Scientific title
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype
Summary
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance.
Cell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour.
The investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.
Patients with histologically or cytologically proven metastatic TNBCPatients whose TNBC has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received Capecitabine or 5-fluorouracil Females aged 21 years and older ECOG performance status 0 or 1 Life expectancy greater than three months Patients have normal organ and marrow function Site(s) of disease amenable to serial bedside biopsies before, during and after study treatment
Study design
Primary purpose:
Treatment, Allocation:
N/A, Intervention model:
Single Group Assignment, Masking:
None (Open Label),
Conditions
Metastatic Triple-Negative Breast Carcinoma
Other study ID numbers
BEXMET
Choose trial site (1)
National Cancer Centre Singapore
11 Hospital Cres, Singapore 169610